Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Biohaven Pharmaceutical HoldingCompany Ltd.

Announced: May 10, 2022
Value: $12.2 billion
Status: Pending

Exclusive financial advisor to Biohaven on its sale to Pfizer

Intelsat S.A.

Announced: February 1, 2022
Value: $8 billion
Status: Pending

Exclusive investment banker to a group of ad hoc lenders throughout Intelsat's chapter 11 proceedings, including a refinancing of existing secured debt and DIP facilities

Cornerstone Building Brands, Inc.

Announced: February 14, 2022
Value: $5.9 billion
Status: Pending

Financial advisor to the Special Committee of Cornerstone's Board of Directors on the sale of shares to Clayton, Dubilier & Rice that CD&R did not already own

R1 RCM Inc.

Announced: January 10, 2022
Value: $4.1 billion
Status: Pending

Lead financial advisor to R1 on its acquisition of Cloudmed

Informa plc

Announced: February 10, 2022
Value: £1.9 billion
Status: Pending

Financial advisor to Informa on the divestiture of its Pharma Intelligence business to Warburg Pincus

Resideo Technologies, Inc.

Announced: February 7, 2022
Value: $593 million
Status: Pending

Exclusive financial advisor to Resideo on its acquisition of First Alert, Inc. from Newell Brands Inc.

Oscar Health, Inc.

Announced: January 27, 2022
Value: $305 million
Status: Pending

Financial advisor to Oscar on its exploration of strategic financing alternatives and sole placement agent on a private placement of convertible senior notes led by Dragoneer Investment Group

PTC Inc

Announced: April 20, 2022
Value: $280 million
Status: Pending

Exclusive financial advisor to PTC on its acquisition of Intland Software

Checkmate Pharmaceuticals

Announced: April 19, 2022
Value: $250 million
Status: Pending

Exclusive financial advisor to Checkmate on its sale to Regeneron Pharmaceuticals

Vauban Infrastructure Partners

Announced: March 9, 2022
Status: Pending

Exclusive financial advisor to Vauban on its purchase of equity in Paprec Group

Kimberly-Clark Corporation

Announced: February 24, 2022
Status: Closed

Exclusive financial advisor to Kimberly-Clark on its acquisition of a majority stake in Thinx, Inc.

Recipharm AB

Announced: February 18, 2022
Status: Pending

Exclusive financial advisor to Recipharm on its acquisition of Vibalogics

Recipharm AB

Announced: February 18, 2022
Status: Pending

Exclusive financial advisor to Recipharm on its acquisition of Arranta Bio

Resonant Inc.

Announced: February 14, 2022
Status: Closed

Lead financial advisor to Resonant on its purchase by Murata Manufacturing Co., Ltd.

Ole Smoky Distillery

Announced: February 11, 2022
Status: Closed

Financial advisor to Ole Smoky on its sale to Apax Partners

Thirty Madison

Announced: February 9, 2022
Status: Pending

Exclusive financial advisor to Thirty Madison on its merger with Nurx

Jacobs Engineering Group Inc.

Announced: February 7, 2022
Status: Pending

Exclusive financial advisor to Jacobs on its acquisition of StreetLight Data, Inc.

Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.